Latitude Pharma's Phospholipid Gel tech gains acceptance

With four new collaborative programs announced, San Diego-based Latitude Pharmaceuticals now has a total of eleven projects underway for its Phospholipid Gel (PG) Depot sustained release drug delivery technology. The parenteral drug delivery platform, for both small and large molecule therapeutics, can deliver up to seven days of low burst, peak-free sustained drug release following a subcutaneous or intramuscular injection. 

Says LPI President, Andrew Chen, PhD, “Our latest projects represent a growing recognition from startups to large pharma of the potential for PG Depot technology. We’re very pleased that our newest collaborators have selected (PG Depot) to overcome the short half-life and frequent injection issues problematic for many emerging medicines, especially proteins and peptides.”

- here’s Latitude's release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.